Journal
JOURNAL OF THE ENDOCRINE SOCIETY
Volume 4, Issue 9, Pages -Publisher
ENDOCRINE SOC
DOI: 10.1210/jendso/bvaa075
Keywords
Cushing syndrome; primary aldosteronism; cAMP; CTNNB1
Categories
Ask authors/readers for more resources
This review reports the main molecular alterations leading to development of benign cortisol- and/or aldosterone-secreting adrenal tumors. Causes of adrenal Cushing syndrome can be divided in 2 groups: multiple bilateral tumors or adenomas secreting cortisol. Bilateral causes are mainly primary pigmented nodular adrenocortical disease, most of the time due to PRKAR1A germline-inactivating mutations, and primary bilateral macronodular adrenal hyperplasia that can be caused in some rare syndromic cases by germline-inactivating mutations of MEN1, APC, and FH and of ARMC5 in isolated forms. PRKACA somatic-activating mutations are the main alterations in unilateral cortisol-producing adenomas. In primary hyperaldosteronism (PA), familial forms were identified in 1% to 5% of cases: familial hyperaldosteronism type I (FH-I) due to a chimeric CYP11B1/CYP11B2 hybrid gene, FII-II due to CLCN-2 germline mutations, FII-III due to KCNJ5 germline mutations, FII-IV due to CACNA1H germline mutations and PA, and seizures and neurological abnormalities syndrome due to CACNAID germline mutations. Several somatic mutations have been found in aldosterone-producing adenomas in KCNJ5, ATP1A1, ATP2B3, CACNA1D, and CTNNB1 genes. In addition to these genetic alterations, genome-wide approaches identified several new alterations in transcriptome, methylome, and miRnome studies, highlighting new pathways involved in steroid dysregulation. (C) Endocrine Society 2020.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available